Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer UTB reductions by Year
UTB reductions — Settlements with taxing authorities ($M) ($M)
Pfizer UTB reductions: $112M in FY2025, down 87.7% from a year earlier.
Latest, FY2025
112
Period ended Dec 31, 2025
Change on a year earlier
-87.7%
911 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Taxes on Income Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB reductions — Settlements with taxing authorities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 112 | -87.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 911 | +971.8% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 85 | -89.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 842 | +3,408.3% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 24 | +60.0% | Form 10-K (filed 2024-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 15 | -85.0% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 100 | -18.7% | Form 10-K (filed 2022-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 123 | +251.4% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 35 | -72.2% | Form 10-K (filed 2020-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 126 | +96.9% | Form 10-K (filed 2019-02-28) ↗ |
| FY2015 | Dec 31, 2015 | 64 | – | Form 10-K (filed 2018-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer UTB reductions ($M), annual FY2015–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/utb-settle
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.